Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Duocarmycin analogs

Antibody-drug conjugates are designed to combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxity. Upon internalization of the ADC, the antibody-bound c...

Laboratory

Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...

OxyContin

OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...

Lyxumia

Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is re...

Synthon Unveils Another ADC Facility

ADCs are a hot topic in drug development even though only two have been approved so far and one of those withdrawn. Regardless, Roche's (Genentech) T-DM1 is widely expected to gain approval in 2013 an...

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, whic...

Synthon Unveils ADC Facility as Data Show Promise for First Candidate

Following a wave of recent investment in ADC production, Synthon has opened an ADC manufacturing facility in Nijmegen, Netherlands, to help bring its first preclinical ADC program to clinical trials b...

Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact

Synthon has entered into a global license agreement with Amgen  and Watson Pharmaceuticals, for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin, which is currently approved for...

Leica Biosystems and Synthon Biopharmaceuticals partner to develop companion diagnostics for cancer

Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of speciality pharmaceutical company Synthon, have agreed to collaborate on the development and commercialisation of a companion diagnosti...

Watson and Amgen take on Synthon's biosimilar Herceptin

Watson has acquired the licence to Synthon's biosimilar version of Herceptin (trastuzumab) for an undisclosed amount. Watson has in turn contributed the product to its biosimilars collaboration with A...

Synthon chooses Avacta’s Optim 1000 for high throughput formulation studies

Pharmaceutical developers at Synthon have chosen an Optim 1000 high throughput, micro-volume protein analysis system...

The metal-carbonylπ(aryl) interaction as a supramolecular synthon for the stabilisation of transition metal carbonyl crystal structures.

M-carbonyl(lone pair)π(aryl) interactions provide stability to their transition metal crystal structures. This supramolecular synthon usually leads to zero- or one-dimensional aggregation patterns; a...

New strategy to construct fused/bridged/spiro carbocyclic scaffolds based on the design of novel 6-C synthon precursor.

In this article we report a new strategy to build fused/spiro/bridged carbocyclic systems with a novel 6-C synthon from readily available diallyl diacetates through the sequential Pd-catalyzed double...

Silyl glyoxylates. Conception and realization of flexible conjunctive reagents for multicomponent coupling.

This Perspective describes the discovery and development of silyl glyoxylates, a new family of conjunctive reagents for use in multicomponent coupling reactions. The selection of the nucleophilic and...

MMT, Npeoc-protected spermine, a valuable synthon for the solid phase synthesis of oligonucleotide oligospermine conjugates via guanidine linkers.

Solid phase spermine oligomerization via guanidine linkers was achieved using activated thiourea coupling reaction with primary amino group. Disymmetric spermine synthon was efficiently synthesised in...

Copper(ii) carboxylate tetramers formed from an enantiopure ligand containing a π-stacking supramolecular synthon: single-crystal to single-crystal enantioselective ligand exchange.

An enantiopure ligand built from connecting the ππ stacking 1,8-naphthalimide supramolecular synthon with l-asparagine, L(asn)(-), forms tetrameric [Cu(4)(L(asn))(8)(py)(MeOH)]. The methanol ligand,...